We utilized CRISPR-Cas9 technology in the murine NSCLC line LLC to generate clonal variants with BIN1 loss-of-function mutations (Supplementary Fig. 2a-d), referred to hereafter as LLC-BIN1KO. The gene discussed is BIN1; the disease is non-small cell lung carcinoma.